Related Experiment Video
Updated: Jul 16, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
Carotid body function in heart failure
1Department of Cellular and Integrative Physiology, University of Nebraska College of Medicine, 985850 Nebraska Medical Center, Omaha, NE 68198-5850, USA. hschultz@unmc.edu
Insights
The carotid body (CB) chemoreflex is enhanced in chronic heart failure (CHF), increasing sympathetic nerve activity (SNA). This involves altered signaling in the CB and central nervous system (CNS), with angiotensin II and nitric oxide playing key roles.
Area of Science:
- Cardiovascular Physiology
- Neuroscience
- Renal Physiology
Background:
- Chronic heart failure (CHF) is associated with elevated sympathetic nerve activity (SNA).
- The carotid body (CB) chemoreflex is implicated in regulating SNA.
- Understanding the CB's role in CHF is crucial for therapeutic development.
Purpose of the Study:
- To review the functional characteristics of the CB chemoreflex in controlling SNA in CHF.
- To elucidate the mechanisms underlying enhanced CB chemoreflex activity in CHF.
- To identify the roles of specific signaling pathways in the CB and CNS.
Main Methods:
- Review of existing literature on CB chemoreflex in CHF.
- Analysis of evidence from both human patients and animal models of CHF.
- Examination of cellular and molecular mechanisms within the CB and CNS.
Main Results:
- The CB chemoreflex is enhanced in CHF, contributing to elevated SNA.
- Altered afferent discharge and ion channel function (K+ currents) in CB glomus cells.
- Downregulation of nitric oxide synthase (NOS)/NO and upregulation of angiotensin II (Ang II)/AT1R signaling in CB glomus cells.
- Central nervous system (CNS) interactions, including altered baroreceptor input and central Ang II, further increase sympathetic drive.
- Impaired NO function in the hypothalamus contributes to enhanced SNA.
Conclusions:
- The enhanced CB chemoreflex in CHF is a multi-faceted adaptation.
- Both the CB and CNS exhibit altered signaling, involving Ang II and NO.
- These complementary mechanisms aim to increase CB chemoreflex function in CHF.
Abstract:
In this review, we summarize the present state of knowledge of the functional characteristics of the carotid body (CB) chemoreflex with respect to control of sympathetic nerve activity (SNA) in chronic heart failure (CHF). Evidence from both CHF patients and animal models of CHF has clearly established that the CB chemoreflex is enhanced in CHF and contributes to the tonic elevation in SNA. This adaptive change derives from altered function at the level of both the afferent and central nervous system (CNS) pathways of the reflex arc. At the level of the CB, an elevation in basal afferent discharge occurs under normoxic conditions in CHF rabbits, and the discharge responsiveness to hypoxia is enhanced. Outward voltage-gated K(+) currents (I(K)) are suppressed in CB glomus cells from CHF rabbits, and their sensitivity to hypoxic inhibition is enhanced. These changes in I(K) derive partly from downregulation of nitric oxide synthase (NOS)/NO signaling and upregulation of angiotensin II (Ang II)/Ang II receptor (AT(1)R) signaling in glomus cells. At the level of the CNS, interactions of the enhanced input from CB chemoreceptors with altered input from baroreceptor and cardiac afferent pathways and from central Ang II further enhance sympathetic drive. In addition, impaired function of NO in the paraventricular nucleus of the hypothalamus participates in the increased SNA response to CB chemoreceptor activation. These results underscore the principle that multiple mechanisms involving Ang II and NO at the level of both the CB and CNS represent complementary and perhaps redundant adaptive mechanisms to enhance CB chemoreflex function in CHF.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Heart Failure I: Introduction